Will a given development in HIV make a difference in the clinic? Will it change practice? Is this something I should know if I take care of people living with HIV? The answer to each of these must be yes for the story to make the list.
Although you may not have known -- or even heard of -- Charles van der Horst, his DNA is woven into the cloth of HIV care and research.
The vaccine for human papillomavirus got a bad rap when it debuted. And yet time has shown it's very effective in reducing cancers linked to HPV.
Two models, one from Washington State and another from Los Angeles County, can be duplicated elsewhere to get people into care, experts say.
Looking back on Poteat’s professional arc, it can appear as though her path toward a leadership role in HIV care was always clear. But there have been plenty of twists in that path.
These social justice-minded researchers at the University of North Carolina-Chapel Hill form a close-knit group that strives to counter stigma and discrimination against people of a gender minority, particularly people of color.
PrEP's success should not be measured by quantity but by quality. The basic level of health care accessibility should allow people high-quality health care provided by premiere providers and frontline staff.
PrEP has been nothing short of revolutionary in changing the landscape of HIV prevention. What has been less discussed are the enormous secondary benefits that have followed the introduction of PrEP.